Logo image of CRDL.CA

CARDIOL THERAPEUTICS INC-A (CRDL.CA) Stock Fundamental Analysis

TSX:CRDL - Toronto Stock Exchange - CA14161Y2006 - Common Stock - Currency: CAD

1.98  +0.03 (+1.54%)

Fundamental Rating

1

Taking everything into account, CRDL scores 1 out of 10 in our fundamental rating. CRDL was compared to 35 industry peers in the Pharmaceuticals industry. While CRDL seems to be doing ok healthwise, there are quite some concerns on its profitability. CRDL has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

CRDL had negative earnings in the past year.
CRDL had a negative operating cash flow in the past year.
CRDL had negative earnings in each of the past 5 years.
In the past 5 years CRDL always reported negative operating cash flow.
CRDL.CA Yearly Net Income VS EBIT VS OCF VS FCFCRDL.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M

1.2 Ratios

CRDL's Return On Assets of -140.58% is on the low side compared to the rest of the industry. CRDL is outperformed by 88.57% of its industry peers.
Looking at the Return On Equity, with a value of -203.47%, CRDL is doing worse than 82.86% of the companies in the same industry.
Industry RankSector Rank
ROA -140.58%
ROE -203.47%
ROIC N/A
ROA(3y)-80.54%
ROA(5y)-81.5%
ROE(3y)-102.38%
ROE(5y)-100.84%
ROIC(3y)N/A
ROIC(5y)N/A
CRDL.CA Yearly ROA, ROE, ROICCRDL.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CRDL so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CRDL.CA Yearly Profit, Operating, Gross MarginsCRDL.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 -10K -20K -30K -40K

4

2. Health

2.1 Basic Checks

Compared to 1 year ago, CRDL has more shares outstanding
CRDL has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, CRDL has a worse debt to assets ratio.
CRDL.CA Yearly Shares OutstandingCRDL.CA Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
CRDL.CA Yearly Total Debt VS Total AssetsCRDL.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

CRDL has an Altman-Z score of -2.43. This is a bad value and indicates that CRDL is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -2.43, CRDL is doing worse than 71.43% of the companies in the same industry.
A Debt/Equity ratio of 0.01 indicates that CRDL is not too dependend on debt financing.
The Debt to Equity ratio of CRDL (0.01) is better than 85.71% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z -2.43
ROIC/WACCN/A
WACCN/A
CRDL.CA Yearly LT Debt VS Equity VS FCFCRDL.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M

2.3 Liquidity

CRDL has a Current Ratio of 3.26. This indicates that CRDL is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 3.26, CRDL belongs to the top of the industry, outperforming 82.86% of the companies in the same industry.
CRDL has a Quick Ratio of 3.26. This indicates that CRDL is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 3.26, CRDL belongs to the best of the industry, outperforming 94.29% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.26
Quick Ratio 3.26
CRDL.CA Yearly Current Assets VS Current LiabilitesCRDL.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

1

3. Growth

3.1 Past

CRDL shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by 0.00%.
EPS 1Y (TTM)0%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%28.57%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, CRDL will show a very strong growth in Earnings Per Share. The EPS will grow by 31.58% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-3%
EPS Next 2Y-22.47%
EPS Next 3Y17.78%
EPS Next 5Y31.58%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CRDL.CA Yearly Revenue VS EstimatesCRDL.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M
CRDL.CA Yearly EPS VS EstimatesCRDL.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 2 3

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CRDL. In the last year negative earnings were reported.
Also next year CRDL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CRDL.CA Price Earnings VS Forward Price EarningsCRDL.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CRDL.CA Per share dataCRDL.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4 -0.6

4.3 Compensation for Growth

CRDL's earnings are expected to grow with 17.78% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-22.47%
EPS Next 3Y17.78%

0

5. Dividend

5.1 Amount

CRDL does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

CARDIOL THERAPEUTICS INC-A

TSX:CRDL (6/13/2025, 7:00:00 PM)

1.98

+0.03 (+1.54%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-14 2025-05-14/amc
Earnings (Next)08-11 2025-08-11
Inst Owners10.17%
Inst Owner ChangeN/A
Ins Owners4.72%
Ins Owner ChangeN/A
Market Cap163.57M
Analysts82.86
Price Target9.95 (402.53%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)31.31%
Min EPS beat(2)29.97%
Max EPS beat(2)32.64%
EPS beat(4)3
Avg EPS beat(4)10.04%
Min EPS beat(4)-47.06%
Max EPS beat(4)32.64%
EPS beat(8)6
Avg EPS beat(8)8.61%
EPS beat(12)10
Avg EPS beat(12)13.6%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-2.18%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 9.3
P/tB 9.3
EV/EBITDA N/A
EPS(TTM)-0.47
EYN/A
EPS(NY)-0.76
Fwd EYN/A
FCF(TTM)-0.31
FCFYN/A
OCF(TTM)-0.31
OCFYN/A
SpS0
BVpS0.21
TBVpS0.21
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -140.58%
ROE -203.47%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-80.54%
ROA(5y)-81.5%
ROE(3y)-102.38%
ROE(5y)-100.84%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 8.83%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.26
Quick Ratio 3.26
Altman-Z -2.43
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)21.14%
Cap/Depr(5y)17.07%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)0%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%28.57%
EPS Next Y-3%
EPS Next 2Y-22.47%
EPS Next 3Y17.78%
EPS Next 5Y31.58%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-32.55%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year23.92%
EBIT Next 3Y39.42%
EBIT Next 5Y46.01%
FCF growth 1Y10.3%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y10.12%
OCF growth 3YN/A
OCF growth 5YN/A